STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Moberg Derma: (STO:MOB) First profitable quarter and licensing agreement with Meda
JANUARY – SEPTEMBER 2011 · Net sales MSEK 35.4 (3.1), an earnings increase of MSEK 32.3 · Research and development expenses MSEK 19.5 (12.9), a cost increase of MSEK 6.5 · Operating loss MSEK -11.4 (-21.2), an improvement of SEK 9.8 · Net loss after tax SEK -10.8 (-22.1), an improvement of MSEK 11.3 · Earnings/loss per share SEK -1.47 (-3.62) · Operating cash flow per share SEK -2.84 (-3.19)
Moberg Derma: (STO:MOB) First profitable quarter and licensing agreement with Meda
JANUARY – SEPTEMBER 2011 · Net sales MSEK 35.4 (3.1), an earnings increase of MSEK 32.3 · Research and development expenses MSEK 19.5 (12.9), a cost increase of MSEK 6.5 · Operating loss MSEK -11.4 (-21.2), an improvement of SEK 9.8 · Net loss after tax SEK -10.8 (-22.1), an improvement of MSEK 11.3 · Earnings/loss per share SEK -1.47 (-3.62) · Operating cash flow per share SEK -2.84 (-3.19)
